Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 868-874

  Nilsson, S ^a   Cislo, P ^b   Sartor, O ^c   Vogelzang, N J ^d   Coleman, R E ^e   O'Sullivan, J M ^f   Reuning Scherer, J ^g   Shan, M ^b   Zhan, L ^b   Parker, C ^h  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Box 5237   (Sweden)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Hematology Oncology   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g YALE UNIVERSITY   (United States)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Castration resistant prostate cancer; Health related quality of life; Patient reported outcomes; Radium 223 dichloride; emitter

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; PLACEBO; RADIUM CHLORIDE RA 223; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; TAXOID;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT RESPONSE; AGED; BONE TUMOR; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEALTH CARE QUALITY; MALE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; STANDARD OF CARE; TAXOIDS; TREATMENT OUTCOME;

EID: 84964770206     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw065     Document Type: Article

References (36)

1. Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2007; 16: 571-575.
2. Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2006; 15: 1297-1306.
3. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-584.
4. Berruti A, Dogliotti L, Bitossi R et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-1253.
5. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer-v1.2015; http:// www.nccn.org/professionals/physician_gls/f_guidelines.asp.
6. Fitzpatrick JM, Bellmunt J, Fizazi K et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50: 1617-1627.
7. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
8. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15: 738-746.
9. Parker C, Heinrich D, Bottomley D et al. Effects of radium-223 dichloride (radium-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Presentation at: Eur J Cancer, 2013; 49 (suppl 2): Abstr 2878.
10. Hoskin P, Sartor O, O'Sullivan JM et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15: 1397-1406.
11. Nilsson S, Tomblyn M, Cislo P et al. Patient-reported quality of life analysis of radium-223 dichloride evaluating pain relief from the phase 3 ALSYMPCA study. J Clin Oncol 2014; 32: Abstr 5069.
12. Nilsson S. Radium-223 dichloride for the treatment of bone metastatic castrationresistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf 2015; 14: 1127-1136.
13. Basch E, Loblaw DA, Oliver TK et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436-3448.
14. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
15. Cella D, Nichol MB, Eton D et al. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009; 12: 124-129.
16. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
17. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
18. Sternberg CN, Molina A, North S et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 2013; 24: 1017-1025.
19. Agresti A, Kateri M. Categorical Data Analysis. Berlin, Heidelberg, Germany: Springer 2011.
20. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007; 5: 70.
21. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002; 11: 207-221.
22. Yost KJ, Eton DT. Combining distribution-and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 2005; 28: 172-191.
23. Neter J, Kutner MH, Wasserman W, Nachtsheim CJ. Applied Linear Statistical Models. Chicago, IL: McGraw-Hill/Irwin 1996: 958-1009; 1010-1044.
24. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997; 2: 64-78.
25. Bottomley D, Vogelzang N, Coleman R et al. Efficacy and safety of radium-223 dichloride by baseline opioid use in patients with castration-resistant prostate cancer and symptomatic bone metastases: results from ALSYMPCA. Presentation at: Global Congress on Prostate Cancer; 4-6 February; Rome, Italy 2015.
26. Nilsson S, Strang P, Aksnes AK et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48: 678-686.
27. Cella D, Ivanescu C, Holmstrom S et al. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol 2015; 26: 179-185.
28. Harland S, Staffurth J, Molina A et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013; 49: 3648-3657.
29. Cislo P, Sartor O, Reuning-Scherer J et al. Effects of radium-223 dichloride on health-related quality of life assessed by the EQ-5D utility scores in ALSYMPCA. Eur Urol 2015; 14: e673-e673a. Abstr 673.
30. Basch E, Abernethy AP, Mullins CD et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012; 30: 4249-4255.
31. Victorson DE, Beaumont JL, Rosenbloom SK et al. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology 2011; 20: 977-983.
32. Cella D, Rosenbloom SK, Beaumont JL et al. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Canc Netw 2011; 9: 268-278.
33. Jones D, Zhao F, Fisch MJ et al. The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 2014; 12: 41-49.
34. Quinten C, Martinelli F, Coens C et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer 2014; 120: 302-311.
35. Chow E, Nguyen J, Zhang L et al. International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 2012; 118: 1457-1465.
36. FACT-BP quality of life measurement in patients with bone pain. www.facit.org/ FACITOrg/Questionnaires 2004.